California Academy of Family Physicians (CAFP)
MAY 14, 2025
However, for individuals who do not qualify for federal Medicaid funding—such as most undocumented immigrants—the federal government does not provide matching funds, even when those individuals meet income eligibility requirements. The asset limit for a household would be $2,000 for an individual and $3,000 per couple.
Pamela Wible MD
MAY 21, 2025
2026 Physician Vision Quest Retreat Dec 3–7, 2025 ~ 1:1 or small group retreat Craving clarity before the new year? Group retreats host 4 to 7 physicians, combining facilitated individual coaching and inspiring group activities. Tax-deductible. CME included. By invitation only. Tax-deductible. 30 hours category 2 CME. Can’t travel?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
MARCH 5, 2024
AstraZeneca also claimed that CMS’s revised guidance on the Negotiation Program for Price Applicability Year 2026 (“Guidance”) interpreted the IRA in two very faulty ways, which violated the Administrative Procedure Act (APA) and harmed and will continue to harm the company. Opinion at 17. see also 42 U.S.C. 1320f-1(e)(1)(A).
FDA Law
OCTOBER 13, 2024
Designed to incentivize the development of drugs for pediatric rare diseases where such development may not otherwise have occurred, vouchers may be granted for drugs for serious or life-threatening rare diseases where the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years.
FDA Law
FEBRUARY 21, 2024
One of the major changes is the extension of the transition period from one to two years, with FDA now planning to enforce the QMSR requirements upon the effective date of the final rule on February 2, 2026. The final rule emphasizes risk management activities and risk-based decision making. FDA further retained some definitions in the QSMR.
FDA Law
FEBRUARY 13, 2025
Post-market surveillance plans and procedures (PMS) are a requirement under ISO 13485 which will be adopted into FDAs Quality Management System Regulation in 2026. The final guidance clarifies that only an unresolvable failure should preclude implementation; if the failure is resolvable the modification may be implemented after retesting.
FDA Law
SEPTEMBER 20, 2021
Notable Dates and Timelines – Program opens, beginning of FY 2023; Expediting reviews fully implemented, by FY 2024; Webpage with detailed criteria for acceptance and participation, October 1, 2022; Interim assessment, end of FY 2025; Public workshop, end of Q2 FY 2026. Notable Dates and Timelines – Applications open, Q4 of FY 2023.
Expert insights. Personalized for you.
204 
Let's personalize your content